About Linearis Ventures
Linearis Ventures is pioneering and supporting discoveries to prevent, detect and cure diseases through direct investments in innovative life sciences companies. Linearis brings together a team of seasoned experts in biomarker discovery, drug development, BioPharma executives, healthcare innovators, the co-father of modern AI and winner of the A.M. Turing Prize, Dr Yoshua Bengio as well as the curator of the Human Metabolome Database, Dr David Wishart. To fundamentally transform our healthcare systems and improve patient care, we must provide novel, non-invasive and easily accessible modalities for better diagnosis, prediction of health status, optimization of treatments and monitoring. Integrated into the VC fund, Linearis Labs' AI-driven differentiating offering is unique in generating disease signatures tailored to elucidate causal relationships underlying human omics and diseases. Its omic signature AI-tailored approach to cancer, diabetes, infectious diseases, NASH and other chronic diseases will accelerate discovery and commercialize new innovative medicines to improve patient care and outcomes.